AbbVie Inc. $ABBV Shares Sold by Fourpath Capital Management LLC

Fourpath Capital Management LLC lowered its stake in AbbVie Inc. (NYSE:ABBV) by 33.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,451 shares of the company’s stock after selling 2,706 shares during the period. Fourpath Capital Management LLC’s holdings in AbbVie were worth $1,246,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ABBV. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the second quarter valued at approximately $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

Shares of NYSE:ABBV opened at $208.22 on Monday. AbbVie Inc. has a 52-week low of $168.54 and a 52-week high of $244.81. The stock’s fifty day simple moving average is $220.35 and its 200-day simple moving average is $224.04. The company has a market capitalization of $368.16 billion, a P/E ratio of 88.23, a P/E/G ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the business earned $2.16 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Insider Buying and Selling at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by corporate insiders.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie’s successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges ‘outdated’ 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie’s guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie’s guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Barclays assumed coverage on AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target on the stock. UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $253.00.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.